Ex vivo treatment of myeloma cells by 4-hydroperoxycyclophosphamide and VP-16-213

C. Shimazaki; S. C. Gulati; J. Atzpodien; J. Fried; O. M. Colvin; B. D. Clarkson

doi:10.1159/000205592

Ex vivo treatment of myeloma cells by 4-hydroperoxycyclophosphamide and VP-16-213

C. Shimazaki, S. C. Gulati, J. Atzpodien, J. Fried, O. M. Colvin, B. D. Clarkson

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

To assess the usefulness of 4-hydroperoxycyclophosphamide (4-HC) and VP-16-213 (VP-16) as a purging agent for myeloma cells in bone marrow (BM) ex vivo, myeloma cell lines (SK-RCS-1, RPMI-8226), lymphoma cell line (SK-DHL-2) and normal BM cells were treated at different concentrations of 4-HC or VP-16. Clonogenic tumor cells from all three cell lines could be reduced by more than 4 logs, when treated alone or as a mixture with irradiated normal BM cells at a 4-HC concentration of 60 μM. Under similar conditions, approximately 1% of the normal BM myeloid progenitor granulocyte-macrophage colony-forming cells survived. These observations support the use of 4-HC for purging myeloma cells for autologous BM transplantation.

Original language	English
Pages (from-to)	17-22
Number of pages	6
Journal	Acta Haematologica
Volume	80
Issue number	1
DOIs	https://doi.org/10.1159/000205592
State	Published - 1988
Externally published	Yes

Access to Document

10.1159/000205592

Cite this

@article{6244618e5d3544618e6dab9e7acef7f4,

title = "Ex vivo treatment of myeloma cells by 4-hydroperoxycyclophosphamide and VP-16-213",

abstract = "To assess the usefulness of 4-hydroperoxycyclophosphamide (4-HC) and VP-16-213 (VP-16) as a purging agent for myeloma cells in bone marrow (BM) ex vivo, myeloma cell lines (SK-RCS-1, RPMI-8226), lymphoma cell line (SK-DHL-2) and normal BM cells were treated at different concentrations of 4-HC or VP-16. Clonogenic tumor cells from all three cell lines could be reduced by more than 4 logs, when treated alone or as a mixture with irradiated normal BM cells at a 4-HC concentration of 60 μM. Under similar conditions, approximately 1% of the normal BM myeloid progenitor granulocyte-macrophage colony-forming cells survived. These observations support the use of 4-HC for purging myeloma cells for autologous BM transplantation.",

author = "C. Shimazaki and Gulati, {S. C.} and J. Atzpodien and J. Fried and Colvin, {O. M.} and Clarkson, {B. D.}",

year = "1988",

doi = "10.1159/000205592",

language = "English",

volume = "80",

pages = "17--22",

journal = "Acta Haematologica",

issn = "0001-5792",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - Ex vivo treatment of myeloma cells by 4-hydroperoxycyclophosphamide and VP-16-213

AU - Shimazaki, C.

AU - Gulati, S. C.

AU - Atzpodien, J.

AU - Fried, J.

AU - Colvin, O. M.

AU - Clarkson, B. D.

PY - 1988

Y1 - 1988

N2 - To assess the usefulness of 4-hydroperoxycyclophosphamide (4-HC) and VP-16-213 (VP-16) as a purging agent for myeloma cells in bone marrow (BM) ex vivo, myeloma cell lines (SK-RCS-1, RPMI-8226), lymphoma cell line (SK-DHL-2) and normal BM cells were treated at different concentrations of 4-HC or VP-16. Clonogenic tumor cells from all three cell lines could be reduced by more than 4 logs, when treated alone or as a mixture with irradiated normal BM cells at a 4-HC concentration of 60 μM. Under similar conditions, approximately 1% of the normal BM myeloid progenitor granulocyte-macrophage colony-forming cells survived. These observations support the use of 4-HC for purging myeloma cells for autologous BM transplantation.

AB - To assess the usefulness of 4-hydroperoxycyclophosphamide (4-HC) and VP-16-213 (VP-16) as a purging agent for myeloma cells in bone marrow (BM) ex vivo, myeloma cell lines (SK-RCS-1, RPMI-8226), lymphoma cell line (SK-DHL-2) and normal BM cells were treated at different concentrations of 4-HC or VP-16. Clonogenic tumor cells from all three cell lines could be reduced by more than 4 logs, when treated alone or as a mixture with irradiated normal BM cells at a 4-HC concentration of 60 μM. Under similar conditions, approximately 1% of the normal BM myeloid progenitor granulocyte-macrophage colony-forming cells survived. These observations support the use of 4-HC for purging myeloma cells for autologous BM transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0023749455&partnerID=8YFLogxK

U2 - 10.1159/000205592

DO - 10.1159/000205592

M3 - Article

C2 - 3135688

AN - SCOPUS:0023749455

SN - 0001-5792

VL - 80

SP - 17

EP - 22

JO - Acta Haematologica

JF - Acta Haematologica

IS - 1

ER -

Ex vivo treatment of myeloma cells by 4-hydroperoxycyclophosphamide and VP-16-213

Abstract

Access to Document

Fingerprint

Cite this